FIELD: pharmacology.
SUBSTANCE: invention relates to combinations for treatment of infections caused by gram-negative bacteria positive for NDM-1 producing carbapenemase. The combination includes fulvic acid or a salt thereof as an active ingredient and meropenem.
EFFECT: increased effectiveness of treatment, while the synergistic effect of fulvic acid and meropenem is observed.
6 cl, 2 dwg, 5 tbl, 2 ex
| Title | Year | Author | Number |
|---|---|---|---|
| AGENT FOR THE TREATMENT OF INFECTIONS CAUSED BY MULTI-RESISTANT BACTERIA, INCLUDING THOSE PRODUCING CARBAPENEMASE | 2022 |
|
RU2793587C1 |
| KLEBSIELLA PNEUMONIAE BACTERIAL STRAIN USED AS A TEST CULTURE FOR THE DETECTION OF THE NDM GENE BY POLYMERASE CHAIN REACTION FOR ACCURATE DIAGNOSIS AND PRESCRIPTION OF ANTIBACTERIAL THERAPY FOR KLEBSIELLA INFECTIONS | 2022 |
|
RU2797025C1 |
| ANTIBACTERIAL HUMIC AGENT | 2020 |
|
RU2753606C1 |
| ANTIMICROBIAL COMBINATION FOR CARBAPENEM-RESISTANT GRAM-NEGATIVE BACTERIA OF THE TYPE KLEBSIELLA PNEUMONIAE PRODUCING METAL-Β-LACTAMASE | 2016 |
|
RU2664434C2 |
| MALDI-TOF MASS SPECTROMETRIC METHOD FOR DETERMINING MICROORGANISM RESISTANCE TO ANTIBACTERIAL PREPARATIONS | 2020 |
|
RU2761096C2 |
| ANTIMICROBIAL COMBINATION IN TERMS OF CARBAPENEM RESISTANTGRAM-NEGATIVE PSEUDOMONAS AERUGINOSA BACTERIA, PRODUCING METAL-β-LACTAMASE | 2015 |
|
RU2618433C2 |
| NEW Β-LACTAMASE INHIBITORS | 2017 |
|
RU2741963C2 |
| COMBINATION THERAPY FOR TREATING NOSOCOMIAL PNEUMONIA | 2014 |
|
RU2684112C2 |
| PHARMACEUTICAL COMPOSITION FOR TREATING BACTERIAL INFECTIONS CAUSED BY THE MAIN PATHOGENS | 2023 |
|
RU2825961C1 |
| POLYMYXIN DERIVATIVES AND USE THEREOF IN A COMBINED THERAPY TOGETHER WITH VARIOUS ANTIBIOTICS | 2014 |
|
RU2730012C2 |
